Alzheimer’s

The disease requires a brain scan or spinal tap to spot one sticky amyloid protein. But a recent study finds that a certain blood test helped improve diagnosis without more costly follow-up procedures.

The GUIDE Model is designed to facilitate comprehensive, coordinated care that improves the quality of life for people with dementia and reduces the strain on their unpaid caregivers.

The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.

President Joe Biden is under pressure to undergo cognitive testing even though his physician says he passes an annual neurologic exam. But what can the brief screening tool actually tell about a person’s brain health?

The clinic will provide two medications that can slow the progression of the disease in early stages: Leqembi and Kisunla. The Roskamp Institute plans to open the facility in September.

A 2023 Alzheimer's Association report notes that 70% of caregivers say coordinating care is stressful. Three out of four say they are concerned for their own health given the stress and difficulty of the job.

A neurologist and neuropathologist address the prevalence, risk factors, early detection signs and preventive measures related to brain diseases.

The FDA will make the final decision on approval later this year. If the agency agrees with advisers, donanemab would only be the second drug approved to slow cognitive decline due to Alzheimer’s.

A sedative shouldn’t be the first thing tried to help people with dementia who exhibit distressing behaviors. A new website is a comprehensive, free resource that offers guidance to caregivers.

Two professors from the nursing college are leading a team of investigators from four other institutions to evaluate how factors like social isolation and intermittent sugar cane burning affect brain health.